←
Professor Matthew C. Kiernan AM Nerve Centrals8,179 posts
Professor Matthew C. Kiernan AM Nerve Centrals avatar

Professor Matthew C. Kiernan AM Nerve Centrals

@nervecentrals

CEO & Executive Director @Neuraustralia Scientia Professor of Neuroscience @UNSW. Neurologist @SEastSydHealth. President @brainfoundoz Editor Emeritus @JNNP_BMJ

◷ Joined October 2010▧ 282 Photos and videos
Neurotorium avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
Neurotorium@neurotorium·Nov 17

Introducing our new theme: ALS–FTD 🧠 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) have traditionally been considered distinct neurodegenerative disorders. However, growing evidence of shared clinical, genetic, and pathological features has fundamentally changed our understanding of their relationship. Today, we're pleased to launch Neurotorium's new theme on the ALS–FTD spectrum, bringing together expert-developed, freely accessible educational resources. Explore our first collection of materials: • Slide deck: History, Definitions and Diagnosis, by Professor Dame Pamela Shaw. • Expert article: Frontotemporal Dementia and Motor Neuron Disease: A Shared Clinical and Biological Landscape, by Professor Matthew Kiernan and Dr Hannah C. Timmins. • Expert video: Professor James Rowe explores why ALS and FTD should be considered within a shared disease spectrum. • Illustrations and FAQs: Visual and accessible resources explaining the relationship between ALS and FTD. Over the coming weeks, we'll be releasing further slide decks and expert resources covering disease progression, cognition and behaviour, treatment, epidemiology, and genetics. Explore the new theme here: neurotorium.org/als-ftd/ #ALS #FTD

Post attachment
JAMA Neurology avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
JAMA Neurology@JAMANeuro·Nov 17

📈 Among cognitively unimpaired adults, higher plasma #pTau217 and older age were associated with higher 5-year and 10-year risk of mild cognitive impairment and dementia, supporting individualized prognosis in preclinical #AlzheimersDisease. ja.ma/48RPMKP

JAMA Neurology avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
JAMA Neurology@JAMANeuro·Nov 14

Among patients with relapsing #MultipleSclerosis, earlier and continuous ocrelizumab treatment was associated with better long-term relapse and disability control than delayed initiation after interferon beta-1a. ja.ma/4zw7kHD

Telegraph Football avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
Telegraph Football@TeleFootball·Nov 11

Exclusive: Prime Minister says football “has a responsibility to the players who have given so much to it and the families now living with the consequences” as he calls for a compensation scheme for the victims of game’s dementia crisis Plus, former Manchester United defender Gary Pallister wants heading restrictions in training ⤵️ telegraph.co.uk/football/202…

Post attachment
Brain avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
Brain@Brain1878·Nov 10

Gibson et al. analysed postmortem brains from over 7000 older adults. Lewy body pathology was present in more than one in four people, with anatomical distributions of pathology differing by sex and showing distinct associations with co-pathologies. shorturl.at/TR9LS

Post attachment
NeuRA (Neuroscience Research Australia) avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
NeuRA (Neuroscience Research Australia)@neuraustralia·Nov 9

For more than 50 years the Brain Foundation has been funding the next generation of Australian research into neurological disorders and diseases, and two NeuRA researchers are among its latest recipients.   Announced at the Art Gallery of NSW, the 2026 Brain Foundation Research Grant program recognised 18 research grant recipients and one prize winner across four Australian states, each aiming to advance our understanding of conditions and improve diagnosis, treatment and outcomes for people living with neurological conditions.   Among them were NeuRA's Clinical Research Manager and Principal Research Scientist, Dr Hannah Timmins and Dr Sharika Raga.   Speaking at the event were Director of the Sydney Brain Bank, Associate Professor Claire Shepherd and President of the Brain Foundation and NeuRA CEO, Professor Matthew Kiernan AM, who shared his perspective on the importance of research funding and the Foundation’s role as the largest priming institution for neuroscience research in Australia.   “The Brain Foundation has sought to identify early- and mid-career researchers through their scientific and research excellence,” he said. “It’s through these early investments that research really starts to take hold. Our aim is to prime that research for take-off, both nationally and internationally.”   “Virtually every neurologist and neuroscientist across Australia has been involved in research funded by the Brain Foundation. It’s a fantastic trajectory, but this is still only the beginning. We want to support much more research going forward.”   Dr Timmins and her team are investigating for a reliable biomarker for MND, via a specific feature called cortical excitability, the assessment for cortical excitability is non-invasive and If successful, this will allow earlier diagnosis and improved tracking of disease progression. Dr Raga's aim is to close the knowledge gap between a gene therapy developed for CTNNB1 syndrome, the most common condition that is misdiagnosed as cerebral palsy in children, and how to objectively assess disease severity and the outcomes that matter most to families. This will ensure they can use meaningful and sensitive outcome measures in the upcoming clinical trial and any future clinical trials.

Post attachmentPost attachmentPost attachmentPost attachment
Medical Xpress avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
Medical Xpress@medical_xpress·Nov 7

A 10-protein blood panel distinguished ALS patients from healthy people with nearly 98% balanced accuracy, outperforming a leading biomarker—but testing against similar conditions is still needed. @EmoryUniversity @NatureComms medicalxpress.com/news/2026-…

JAMA Psychiatry avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
JAMA Psychiatry@JAMAPsych·Nov 6

Among adults with serious mental illness, #GLP1 receptor agonists vs #SGLT2 inhibitors were associated with lower mortality and fewer major cardiovascular events, with greater absolute benefit in serious mental illness. ja.ma/3UysZQH

Neurotorium avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
Neurotorium@neurotorium·Nov 5

In most neurodegenerative dementias, symptoms reflect neuron loss caused by the slow buildup of misfolded proteins in the brain. This process is called proteinopathy. In Alzheimer’s disease, for example, these proteins are amyloid-β and tau. Some points to remember: -Different proteinopathies can produce similar symptoms when they affect the same brain circuits. -Protein accumulation can begin a decade or more before the first symptoms. -Vascular disease also contributes, and mixed pathology is common in older patients. Learn the basics of the definition and diagnosis of Alzheimer’s disease in our free, referenced slide deck: neurotorium.org/slidedeck/al…

Post attachment
NeuRA (Neuroscience Research Australia) avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
NeuRA (Neuroscience Research Australia)@neuraustralia·Nov 4

In NeuRA's final All Staff Meeting for the year, the team took a moment to celebrate the successes, but also look to the opportunities that lay ahead. In a conversation between Director of Communications, Tom Smithies, and Dr Steve Kassem, we heard about the Brain Mapping Lab's work to enhance our understanding of both child and adult brains through the development of high-resolution atlases. Research support was highlighted through presentations from Alex Economides and Vyoma Patel, as well as Dr Peter Humburg from UNSW's Stats Central. Director of People and Culture, Lisa Ucles, announced a new initiative to recognise staff, whilst Finance Director, Simon To, gave a snapshot of the 2026 position and next year's outlook. NeuRA CEO and Institute Director, Professor Matthew Kiernan AM, provided an update on recent events here at NeuRA, including a visit from the Governor-General with FightMND; affiliation committee meetings with SESLHD and UNSW; and a new partnership with the Sydney Children's Hospital Network. Prof Kiernan then shared a video highlighting some of the year's successes, including grant funding secured, media coverage and philanthropic gifts. Finally, EMCC's James Morched challenged us all with a trivia warm-up ahead of the committee's biannual Trivia Night. Comment your answer below, no cheating!

Post attachmentPost attachmentPost attachmentPost attachment
Brain avatar
⟳ Professor Matthew C. Kiernan AM Nerve Centrals retweeted
Brain@Brain1878·Nov 3

Hayes et al. explore how Alzheimer’s pathology affects the relationship between vascular neuropathology and cognitive scores. shorturl.at/NHyQq

Post attachment